Venus Concept (VERO)
Market Price (12/26/2025): $1.69 | Market Cap: $3.1 MilSector: Health Care | Industry: Life Sciences Tools & Services
Venus Concept (VERO)
Market Price (12/26/2025): $1.69Market Cap: $3.1 MilSector: Health CareIndustry: Life Sciences Tools & Services
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Megatrend and thematic driversMegatrends include Health & Wellness Trends. Themes include Aesthetic Medical Devices, and Anti-Aging & Rejuvenation. | Weak multi-year price returns2Y Excs Rtn is -130%, 3Y Excs Rtn is -178% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -35 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -59% |
| Debt is significantNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 867% | ||
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -12%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -18%, Rev Chg QQuarterly Revenue Change % is -8.2% | ||
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -35%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -35% | ||
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -1673% | ||
| High stock price volatilityVol 12M is 1056% | ||
| Key risksVERO key risks include [1] severe financial distress with a very high probability of bankruptcy and [2] operational inefficiencies causing deteriorating gross margins. |
| Megatrend and thematic driversMegatrends include Health & Wellness Trends. Themes include Aesthetic Medical Devices, and Anti-Aging & Rejuvenation. |
| Weak multi-year price returns2Y Excs Rtn is -130%, 3Y Excs Rtn is -178% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -35 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -59% |
| Debt is significantNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 867% |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -12%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -18%, Rev Chg QQuarterly Revenue Change % is -8.2% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -35%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -35% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -1673% |
| High stock price volatilityVol 12M is 1056% |
| Key risksVERO key risks include [1] severe financial distress with a very high probability of bankruptcy and [2] operational inefficiencies causing deteriorating gross margins. |
Why The Stock Moved
Qualitative Assessment
AI Analysis | Feedback
Following a challenging period between August 31, 2025, and December 26, 2025, Venus Concept (VERO) experienced a stock decline, with key factors emerging from its third-quarter 2025 financial results.1. Significant Revenue Decline in Q3 2025: Venus Concept reported an 8% decrease in revenue for the third quarter of 2025, totaling $13.8 million, compared to $15.0 million in the same quarter of the previous year. This drop was largely attributed to weaker U.S. demand for aesthetic devices, alongside increased U.S. tariff costs and reduced production volumes that pushed unit costs higher.
2. Widened Net Loss: The company's net loss expanded considerably to $22.6 million, or $12.14 per share, in Q3 2025. This figure significantly missed the consensus estimate of $3.68 per share. The increased loss was primarily driven by a $9.5 million operating loss, higher interest and legal expenses, and a one-time charge of $1.2 million related to the divestiture of its Venus Hair business.
Show more
Stock Movement Drivers
Fundamental Drivers
The -24.5% change in VERO stock from 9/25/2025 to 12/25/2025 was primarily driven by a -27.4% change in the company's Shares Outstanding (Mil).| 9252025 | 12252025 | Change | |
|---|---|---|---|
| Stock Price ($) | 2.33 | 1.76 | -24.46% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 60.11 | 58.88 | -2.05% |
| P/S Multiple | 0.06 | 0.06 | -1.74% |
| Shares Outstanding (Mil) | 1.46 | 1.86 | -27.42% |
| Cumulative Contribution | -30.14% |
Market Drivers
9/25/2025 to 12/25/2025| Return | Correlation | |
|---|---|---|
| VERO | -24.5% | |
| Market (SPY) | 4.9% | 28.6% |
| Sector (XLV) | 16.2% | -8.2% |
Fundamental Drivers
The -20.0% change in VERO stock from 6/26/2025 to 12/25/2025 was primarily driven by a -162.2% change in the company's Shares Outstanding (Mil).| 6262025 | 12252025 | Change | |
|---|---|---|---|
| Stock Price ($) | 2.20 | 1.76 | -20.00% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 61.00 | 58.88 | -3.48% |
| P/S Multiple | 0.03 | 0.06 | 117.32% |
| Shares Outstanding (Mil) | 0.71 | 1.86 | -162.20% |
| Cumulative Contribution | -230.47% |
Market Drivers
6/26/2025 to 12/25/2025| Return | Correlation | |
|---|---|---|
| VERO | -20.0% | |
| Market (SPY) | 13.1% | 23.0% |
| Sector (XLV) | 16.6% | -2.5% |
Fundamental Drivers
The -55.6% change in VERO stock from 12/25/2024 to 12/25/2025 was primarily driven by a -162.2% change in the company's Shares Outstanding (Mil).| 12252024 | 12252025 | Change | |
|---|---|---|---|
| Stock Price ($) | 3.96 | 1.76 | -55.56% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 67.20 | 58.88 | -12.39% |
| P/S Multiple | 0.04 | 0.06 | 33.01% |
| Shares Outstanding (Mil) | 0.71 | 1.86 | -162.20% |
| Cumulative Contribution | -172.48% |
Market Drivers
12/25/2024 to 12/25/2025| Return | Correlation | |
|---|---|---|
| VERO | -55.6% | |
| Market (SPY) | 15.8% | 7.1% |
| Sector (XLV) | 13.3% | 0.1% |
Fundamental Drivers
The -96.4% change in VERO stock from 12/26/2022 to 12/25/2025 was primarily driven by a -370.0% change in the company's Shares Outstanding (Mil).| 12262022 | 12252025 | Change | |
|---|---|---|---|
| Stock Price ($) | 49.50 | 1.76 | -96.44% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 107.84 | 58.88 | -45.41% |
| P/S Multiple | 0.18 | 0.06 | -69.39% |
| Shares Outstanding (Mil) | 0.40 | 1.86 | -369.98% |
| Cumulative Contribution | -145.12% |
Market Drivers
12/26/2023 to 12/25/2025| Return | Correlation | |
|---|---|---|
| VERO | -86.6% | |
| Market (SPY) | 48.3% | 7.1% |
| Sector (XLV) | 18.5% | 1.5% |
Price Returns Compared
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| VERO Return | -63% | -2% | -81% | -75% | -68% | -58% | -100% |
| Peers Return | � | 52% | -47% | -0% | -21% | 20% | � |
| S&P 500 Return | 16% | 27% | -19% | 24% | 23% | 18% | 115% |
Monthly Win Rates [3] | |||||||
| VERO Win Rate | 42% | 50% | 42% | 17% | 33% | 25% | |
| Peers Win Rate | � | 62% | 40% | 52% | 40% | 48% | |
| S&P 500 Win Rate | 58% | 75% | 42% | 67% | 75% | 73% | |
Max Drawdowns [4] | |||||||
| VERO Max Drawdown | -64% | -31% | -90% | -81% | -75% | -93% | |
| Peers Max Drawdown | � | -3% | -58% | -29% | -41% | -37% | |
| S&P 500 Max Drawdown | -31% | -1% | -25% | -1% | -2% | -15% | |
[1] Cumulative total returns since the beginning of 2020
[2] Peers: BHC, ABBV, APYX, SKIN, CNMD.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 12/24/2025 (YTD)
How Low Can It Go
| Event | VERO | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -98.2% | -25.4% |
| % Gain to Breakeven | 5488.5% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -79.6% | -33.9% |
| % Gain to Breakeven | 391.0% | 51.3% |
| Time to Breakeven | Not Fully Recovered days | 148 days |
| 2018 Correction | ||
| % Loss | -98.1% | -19.8% |
| % Gain to Breakeven | 5291.3% | 24.7% |
| Time to Breakeven | Not Fully Recovered days | 120 days |
Compare to A, ATEC, CERS, BLLN, FEED
In The Past
Venus Concept's stock fell -98.2% during the 2022 Inflation Shock from a high on 2/19/2021. A -98.2% loss requires a 5488.5% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth over time.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
Venus Concept Inc., a medical technology company, develops, commercializes, and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies, and related services in the United States and internationally. Its product portfolio includes aesthetic device platforms, including Venus Legacy, a noninvasive device used in dermatological and general surgical procedures for females; Venus Versa, a multi-application device used in aesthetic and cosmetic procedures; and Venus Viva, an advanced, portable, and fractional RF system for dermatological procedures requiring ablation and resurfacing of the skin. The company also offers Venus Fiore, a device that delivers non-thermal RF with massage and magnetic field pulses to treat various medical conditions; Venus Bliss, a device for non-invasive lipolysis of the abdomen and flanks in individuals with a body mass index of 30 or less; Venus Glow, a dermabrasion device used to improve skin appearance; and NeoGraft, an advanced hair restoration technology with an automated FUE and implantation system. In addition, it provides Venus Velocity and Venus Epileve for hair removal, permanent hair reduction, and treatment of pseudofolliculitis barbae; and ARTAS iX, a robotic system to assist physicians in identifying and extracting hair follicles units from the scalp during hair transplantation, creating recipient sites, and implanting the harvested hair follicles. The company is headquartered in Toronto, Canada.
AI Analysis | Feedback
Here are 1-2 brief analogies for Venus Concept (VERO):
- Align Technology for cosmetic clinics.
- Intuitive Surgical for non-invasive cosmetic treatments.
AI Analysis | Feedback
- Venus Versa™: A versatile multi-treatment platform offering intense pulsed light (IPL) for skin rejuvenation, hair removal, and various radiofrequency (RF) applications for skin tightening and anti-aging.
- Venus Legacy™: A non-invasive device that uses Multi-Polar Radio Frequency and Pulsed Electro Magnetic Fields to effectively reduce wrinkles, tighten skin, and diminish cellulite.
- Venus Viva™ MD: A fractional radiofrequency (RF) system designed for advanced skin resurfacing, reducing the appearance of wrinkles, scars, and improving overall skin texture.
- Venus Bliss™: Combines diode laser technology for non-invasive fat reduction with multi-polar radiofrequency for skin tightening and cellulite reduction on the body.
- NeoGraft®: An automated Follicular Unit Extraction (FUE) and implantation system for minimally invasive hair restoration procedures.
- ARTAS®: A robotic system that assists physicians in performing precise and efficient follicular unit extraction (FUE) for hair transplantation.
- Venus Glow™: A dermal rejuvenation system utilizing a vacuum, 360-degree rotating tip, and saline jet to cleanse pores, remove impurities, and hydrate the skin.
AI Analysis | Feedback
Venus Concept (symbol: VERO) primarily sells its medical aesthetic devices and related services to other businesses (B2B).
However, the company's customer base is highly fragmented, consisting of thousands of individual medical aesthetic practices, dermatology clinics, plastic surgery offices, and medical spas worldwide. These customers are typically private businesses and not large, publicly traded corporate entities.
Therefore, Venus Concept does not disclose specific "major customer companies" that are publicly traded with associated stock symbols, as no single customer or group of related customers accounts for a significant portion of the company's revenue.
AI Analysis | Feedback
nullAI Analysis | Feedback
Rajiv De Silva, Chief Executive Officer
Rajiv De Silva previously served as President, Chief Executive Officer, and Director of Endo International Plc, a publicly traded, multinational pharmaceutical corporation. He was also the President of Valeant Pharmaceuticals International (now Bausch Health), where he additionally served as Chief Operating Officer of the company's Specialty Pharmaceuticals business, including its dermatology and aesthetics unit. Prior to that, Mr. De Silva held various leadership positions within Novartis AG, including President of Novartis Pharma Canada. He began his career in healthcare at McKinsey & Company in 1995, where he rose to Partner.
Domenic Della Penna, Executive Vice President and Chief Financial Officer
Domenic Della Penna brings considerable expertise to Venus Concept, having held senior posts at several industry-leading multinationals such as Teva Pharmaceuticals, Diageo, and Nestle. Most recently, he was the CFO of Intellipharmaceutics International Inc., a Nasdaq and TSX listed public company. Mr. Della Penna also gained private equity experience through a successful mandate as CFO of Timothy's Coffees of The World. He has made significant contributions to numerous mergers, acquisitions, divestitures, financial systems, and organizational change mandates. He is a C.A., CPA, and holds an MBA from the Schulich School of Business at York University (Toronto).
Melissa Kang, Chief Product Officer
Melissa Kang has over 25 years of experience in marketing, sales management, consulting, and business development. She has owned her own business and managed global brands such as BOTOX Cosmetic®. She holds a BSc in Chemistry from the University of Western Ontario, an MBA from Queen's University, and is a CPA, CMA.
Michael Mandarello, Chief Legal Officer & Head of Strategy & Operations
Michael Mandarello brings more than 10 years of experience providing legal and strategic advice. He took on an expanded role overseeing corporate strategy and operational execution in February 2025.
Kirk Gunhus, Chief Revenue Officer
Kirk Gunhus was appointed Chief Revenue Officer in February 2025, with global responsibility for Venus Concept's sales efforts. He is a seasoned aesthetics industry professional with over 20 years of experience leading commercial organizations in international markets at companies such as Medicis, Zeltiq, Sientra, and MiraDry.
AI Analysis | Feedback
Key Risks to Venus Concept (VERO)
- Significant Financial Challenges and High Risk of Bankruptcy: Venus Concept faces substantial financial difficulties, including a consistent decline in total revenue, negative profitability with ongoing net losses, negative earnings per share (EPS), and a negative net margin. The company has high debt levels, with total debt obligations ranging between approximately $30.1 million and $35.5 million, and a debt-to-equity ratio of 15.93. Its limited liquidity, evidenced by a current ratio of 1.1 and low cash and cash equivalents, further exacerbates these concerns. An Altman Z-Score of -8.22 indicates a very high probability of bankruptcy, estimated at 86%.
- Macroeconomic Headwinds and Customer Financing Pressures: The company's business operations are significantly impacted by "customer financing pressures, economic uncertainty and tight credit markets". These macroeconomic factors have consistently led to declining sales, particularly affecting the aesthetic capital equipment sector and the adoption of robotic systems in the Venus Hair business, with notable weakness in the U.S. market.
- Operational Inefficiencies and Gross Margin Pressure: Venus Concept grapples with operational inefficiencies, resulting in persistent profitability issues and a negative operating margin. While the gross margin remains relatively healthy, it has shown deterioration, which is attributed to pricing pressure, unfavorable product mix shifts, and the impact of U.S. tariffs on imported devices.
AI Analysis | Feedback
The clear emerging threat to Venus Concept (VERO) is the widespread adoption and increasing efficacy of GLP-1 agonist medications (e.g., Ozempic, Wegovy, Mounjaro) for weight loss and fat reduction. These pharmaceutical treatments offer patients a non-surgical and highly effective method for achieving significant weight reduction. As these medications become more accessible and prescribed, they pose a direct challenge to the demand for non-invasive body contouring and fat reduction devices, which constitute a significant portion of Venus Concept's product offerings.
AI Analysis | Feedback
Venus Concept (symbol: VERO) operates primarily in the global medical aesthetic technology and hair restoration markets. The addressable markets for their main products and services are substantial, as detailed below:
Global Medical Aesthetics Market
- The global medical aesthetics market was valued at approximately USD 25.88 billion in 2024 and is projected to reach around USD 87.84 billion by 2034, growing at a Compound Annual Growth Rate (CAGR) of 13% from 2024 to 2034.
- Another estimate places the global market at USD 17.10 billion in 2025, projected to reach USD 27.92 billion by 2030, with a CAGR of 10.30%.
- The global market for medical aesthetic devices was valued at USD 20.1 billion in 2023 and is forecast to grow at a CAGR of 11.3% to reach USD 37.9 billion by the end of 2029.
U.S. Medical Aesthetics Market
- The U.S. aesthetic medicine market size was estimated at USD 37.94 billion in 2023 and is projected to grow at a CAGR of 13.4% from 2024 to 2030, reaching USD 90.82 billion by 2030.
- The U.S. medical aesthetics market size was calculated at USD 9.82 billion in 2024 and is projected to be worth around USD 33.98 billion by 2034, growing at a CAGR of 13.2% from 2024 to 2034.
- North America held more than 40% of the global revenue with a market size of USD 6.338 billion in 2024.
Global Hair Restoration Market
- The global hair restoration market size was estimated at USD 6,463.0 million in 2023 and is projected to reach USD 18,923.4 million by 2030, growing at a CAGR of 16.6% from 2024 to 2030.
- The global hair restoration services market size was approximately USD 7.52 billion in 2024 and is predicted to grow to around USD 34.17 billion by 2034, with a CAGR of roughly 16.35% between 2025 and 2034.
- Another estimate states the global hair restoration market is valued at USD 7.46 billion in 2025 and is expected to reach USD 21.73 billion by 2032, exhibiting a CAGR of 16.5% from 2025 to 2032.
U.S. Hair Restoration Market
- The hair transplant market in the U.S. dominated the industry with a revenue share of 80.33% in 2023.
Global Skin Resurfacing Market
- The global skin resurfacing market was valued at USD 5.6 billion in 2024 and is expected to reach USD 9.0 billion by 2030, confirming a robust CAGR of 8.1%.
- The global skin resurfacing devices market is valued at USD 358.05 million in 2025 and is forecast to reach USD 538.38 million by 2030, advancing at an 8.5% CAGR.
Global Body Contouring Market
- The global body contouring devices market size was estimated at USD 1.75 billion in 2024 and is expected to hit around USD 6.67 billion by 2034, growing at a CAGR of 14.32% from 2025 to 2034.
- The global non-invasive body contouring devices market is forecast to reach USD 5,195.9 million by 2030, at a CAGR of 6.7% during the forecast period 2024-2030.
- The global non-invasive fat reduction market size is calculated at USD 1.87 billion in 2024 and is projected to reach around USD 8.74 billion by 2034, expanding at a CAGR of 17.04% between 2025 and 2034.
U.S. Body Contouring Market
- The U.S. body contouring devices market size was exhibited at USD 520 million in 2024 and is predicted to surpass around USD 1,990 million by 2034, growing at a CAGR of 14.36% from 2025 to 2034.
- North America dominated the global body contouring devices market with the largest market share of 78% in 2024.
Global Cellulite Reduction Market
- The global cellulite treatment market size was valued at USD 2.4 billion in 2024 and is expected to grow from USD 2.6 billion in 2025 to USD 6.5 billion in 2034, at a CAGR of 10.7%.
- The global cellulite reduction devices market size was over USD 361.8 million in 2025 and is estimated to reach USD 955.9 million by the end of 2035, expanding at a CAGR of 11.4% during the forecast timeline, i.e., 2026-2035.
U.S. Cellulite Reduction Market
- In 2024, the U.S. cellulite treatment market accounted for USD 763.7 million in market revenue and is anticipated to grow at a CAGR of 10% between the 2025 to 2034 period.
Global Acne Treatment Market
- The global acne treatment market size is estimated at USD 7.2 billion in 2024 and is forecasted to reach USD 12.44 billion by 2034, advancing at a CAGR of 5.6% between 2024 and 2034.
- Another report states the global acne treatment market size was valued at USD 11.62 billion in 2024 and is projected to grow from USD 12.19 billion in 2025 to USD 17.48 billion by 2032, exhibiting a CAGR of 5.3% during the forecast period.
North America Acne Treatment Market
- North America dominated the acne treatment market with a market share of 49.14% in 2023.
- The North America acne treatment market size was USD 5.70 billion in 2024.
- The U.S. acne treatment market size was exhibited at USD 2.79 billion in 2024 and is projected to be worth around USD 4.88 billion by 2034, growing at a CAGR of 5.84% from 2025 to 2034.
AI Analysis | Feedback
Venus Concept (VERO) is anticipated to drive future revenue growth over the next 2-3 years through several key initiatives:
- Launch and global rollout of Venus NOVA: The company recently received FDA 510(k) clearance for its next-generation multi-application platform, Venus NOVA, with U.S. commercial availability slated for December 2025 and a global rollout planned for 2026. This new platform, a key part of Venus Concept's strategic turnaround and new R&D strategy, is designed for non-invasive body, face, and skin treatments, integrating technologies like Adaptive EMS, MP² RF+PEMF, and IoT connectivity. It is also positioned to address the growing market segment of patient needs linked to GLP-1 medication use.
- Expansion into international markets: Venus Concept expects to see future revenue growth from strategic expansion in international markets. The company has introduced and certified key products in markets such as Australia and India. Furthermore, a 60% increase in sales to distributors in Q3 2024 suggests successful repositioning in these international markets. The global rollout of Venus NOVA in 2026 will also contribute to this international expansion.
- Strategic shift towards cash system sales: Venus Concept is prioritizing cash system sales, a strategy that has proven effective, with cash-based sales representing a significant 76% of U.S. system sales in Q3 2024. This shift aims to improve the company's financial performance and reduce its reliance on lease revenue, which experienced a 39% decrease.
- Growth of recently launched products like Venus Versa Pro: The commercial launch of the multi-application Venus Versa Pro in the United States in November 2023 is expected to contribute to revenue. This platform supports 10 different applicators for a broad range of aesthetic conditions and represents the first platform product under the company's Venus Aesthetic Intelligence ("Venus AI") rebrand, with additional product launches under this branding anticipated in 2024.
AI Analysis | Feedback
Share Issuance
- In December 2020, Venus Concept announced the pricing of a public offering of common stock and warrants, expecting to raise approximately $22.5 million for general corporate purposes, including funding research and development activities.
- In May 2020, the company completed a private placement of approximately $22.25 million in securities, including common stock, preferred stock, and warrants, to a group of investors including EW Healthcare Partners, HealthQuest Capital, and SEDCO Capital.
- Throughout 2025, Venus Concept conducted several registered direct offerings, including approximately $1.1 million in April 2025, and an additional $1.57 million in April 2025, with gross proceeds from both offerings totaling approximately $2.7 million for general corporate purposes. The company also had a registered direct offering in June 2025 for $1.15 million with potential for an additional $2.3 million from warrants.
Inbound Investments
- Venus Concept secured approximately $22.25 million in May 2020 through a private placement of securities to strategic healthcare industry investors.
- The company received an additional $2 million in funding in April 2025 through its ongoing Bridge Financing agreement with Madryn Health Partners.
- Venus Concept completed several debt-to-equity exchange transactions, including $11.0 million of subordinated convertible notes for preferred stock in April 2025, $6.5 million in July 2025, and $11.48 million in October 2025. These transactions reduced total debt obligations by 14% and 24% respectively, bolstering financial flexibility.
Outbound Investments
- In June 2025, Venus Concept entered into a definitive agreement to sell its Venus Hair business to Meta Healthcare Group for $20 million in an all-cash transaction. This divestiture aims to enhance the company's financial stability and allow it to focus on its core medical aesthetics operations.
Latest Trefis Analyses
| Title | Topic | |
|---|---|---|
| DASHBOARDS | ||
| How Low Can Venus Concept Stock Really Go? | Return |
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to VERO. For more, see Trefis Trade Ideas.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 11142025 | CRL | Charles River Laboratories International | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 21.1% | 21.1% | -3.7% |
| 11142025 | GDRX | GoodRx | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | -6.7% | -6.7% | -11.8% |
| 11142025 | ASTH | Astrana Health | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 16.7% | 16.7% | -5.5% |
| 11142025 | SGRY | Surgery Partners | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 2.3% | 2.3% | -1.4% |
| 11072025 | TFX | Teleflex | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 11.8% | 11.8% | -5.1% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons for Venus Concept
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 5.39 |
| Mkt Cap | 0.7 |
| Rev LTM | 825 |
| Op Inc LTM | 54 |
| FCF LTM | 92 |
| FCF 3Y Avg | 63 |
| CFO LTM | 103 |
| CFO 3Y Avg | 77 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 1.6% |
| Rev Chg 3Y Avg | 0.3% |
| Rev Chg Q | 6.0% |
| QoQ Delta Rev Chg LTM | 1.5% |
| Op Mgn LTM | -0.3% |
| Op Mgn 3Y Avg | -5.1% |
| QoQ Delta Op Mgn LTM | 0.3% |
| CFO/Rev LTM | 12.6% |
| CFO/Rev 3Y Avg | 6.8% |
| FCF/Rev LTM | 11.1% |
| FCF/Rev 3Y Avg | 3.7% |
Price Behavior
Price Behavior
| Market Price | $1.76 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 10/12/2017 | |
| Distance from 52W High | -80.3% | |
| 50 Days | 200 Days | |
| DMA Price | $1.98 | $2.43 |
| DMA Trend | down | down |
| Distance from DMA | -11.2% | -27.6% |
| 3M | 1YR | |
| Volatility | 108.0% | 1,064.5% |
| Downside Capture | 255.22 | 139.60 |
| Upside Capture | 67.69 | 38.48 |
| Correlation (SPY) | 28.4% | 7.2% |
VERO Betas & Captures as of 11/30/2025
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 3.21 | 2.51 | 2.33 | 2.14 | 3.75 | 2.46 |
| Up Beta | 8.47 | 4.25 | 4.43 | 3.99 | 15.17 | 10.96 |
| Down Beta | 6.47 | 2.50 | 2.86 | 2.88 | -0.81 | -0.32 |
| Up Capture | 85% | 128% | 94% | 58% | 46% | -4% |
| Bmk +ve Days | 13 | 26 | 39 | 74 | 142 | 427 |
| Stock +ve Days | 10 | 17 | 28 | 50 | 105 | 315 |
| Down Capture | 174% | 238% | 184% | 161% | 118% | 97% |
| Bmk -ve Days | 7 | 16 | 24 | 52 | 107 | 323 |
| Stock -ve Days | 8 | 22 | 30 | 63 | 128 | 405 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Comparison of VERO With Other Asset Classes (Last 1Y) | |||||||
|---|---|---|---|---|---|---|---|
| VERO | Sector ETF | Equity | Gold | Commodities | Real Estate | Bitcoin | |
| Annualized Return | -49.5% | 16.4% | 19.2% | 71.9% | 8.9% | 6.0% | -10.1% |
| Annualized Volatility | 1,056.0% | 17.3% | 19.5% | 19.3% | 15.3% | 17.1% | 35.0% |
| Sharpe Ratio | 0.94 | 0.72 | 0.78 | 2.69 | 0.36 | 0.18 | -0.12 |
| Correlation With Other Assets | 0.1% | 7.1% | 6.4% | 7.5% | -0.3% | 11.3% | |
ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Comparison of VERO With Other Asset Classes (Last 5Y) | |||||||
|---|---|---|---|---|---|---|---|
| VERO | Sector ETF | Equity | Gold | Commodities | Real Estate | Bitcoin | |
| Annualized Return | -65.3% | 8.6% | 14.9% | 18.7% | 11.7% | 4.8% | 32.7% |
| Annualized Volatility | 486.0% | 14.5% | 17.1% | 15.5% | 18.7% | 18.9% | 48.7% |
| Sharpe Ratio | 0.33 | 0.41 | 0.70 | 0.97 | 0.51 | 0.17 | 0.60 |
| Correlation With Other Assets | 2.7% | 7.0% | 5.0% | 3.7% | 1.9% | 5.6% | |
ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Comparison of VERO With Other Asset Classes (Last 10Y) | |||||||
|---|---|---|---|---|---|---|---|
| VERO | Sector ETF | Equity | Gold | Commodities | Real Estate | Bitcoin | |
| Annualized Return | -68.9% | 9.8% | 14.7% | 14.9% | 6.9% | 5.2% | 69.3% |
| Annualized Volatility | 387.4% | 16.6% | 18.0% | 14.8% | 17.6% | 20.8% | 55.8% |
| Sharpe Ratio | 0.19 | 0.48 | 0.70 | 0.83 | 0.31 | 0.22 | 0.90 |
| Correlation With Other Assets | 4.2% | 7.9% | 4.6% | 5.0% | 3.7% | 3.9% | |
ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 11/13/2025 | -8.0% | 1.1% | -10.7% |
| 8/14/2025 | -5.3% | -0.8% | -6.9% |
| 3/31/2025 | 1.5% | -14.2% | -11.5% |
| 11/13/2024 | -10.0% | -16.2% | -1.5% |
| 8/13/2024 | -11.9% | -3.2% | -15.7% |
| 4/1/2024 | 2.7% | 5.5% | -5.9% |
| 11/14/2023 | -0.7% | -8.9% | -48.0% |
| 8/14/2023 | 4.3% | -0.2% | -11.0% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 6 | 7 | 6 |
| # Negative | 13 | 12 | 13 |
| Median Positive | 3.2% | 5.8% | 13.4% |
| Median Negative | -8.0% | -15.3% | -15.7% |
| Max Positive | 4.8% | 12.0% | 46.2% |
| Max Negative | -24.3% | -44.6% | -48.0% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 9302025 | 11132025 | 10-Q 9/30/2025 |
| 6302025 | 8142025 | 10-Q 6/30/2025 |
| 3312025 | 5152025 | 10-Q 3/31/2025 |
| 12312024 | 3312025 | 10-K 12/31/2024 |
| 9302024 | 11132024 | 10-Q 9/30/2024 |
| 6302024 | 8132024 | 10-Q 6/30/2024 |
| 3312024 | 5152024 | 10-Q 3/31/2024 |
| 12312023 | 4012024 | 10-K 12/31/2023 |
| 9302023 | 11142023 | 10-Q 9/30/2023 |
| 6302023 | 8142023 | 10-Q 6/30/2023 |
| 3312023 | 5152023 | 10-Q 3/31/2023 |
| 12312022 | 3272023 | 10-K 12/31/2022 |
| 9302022 | 11102022 | 10-Q 9/30/2022 |
| 6302022 | 8122022 | 10-Q 6/30/2022 |
| 3312022 | 5122022 | 10-Q 3/31/2022 |
| 12312021 | 3282022 | 10-K 12/31/2021 |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.